Reactivos e instrumentos para inmunología, biología celular y biología molecular.
 
> Deuruxolitinib [1513883-39-0]

Deuruxolitinib [1513883-39-0]

Imprimir Imprimir
Por favor conéctese

Referencia HY-50856S-1mg

embalaje : 1mg

Marca : MedChemExpress

product ref is: HY-50856S-1mg

Contact local distributor :


Teléfono : +1 850 650 7790
Deuruxolitinib [1513883-39-0]

Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).

Para uso exclusivo en investigación. No vendemos a pacientes.

Deuruxolitinib Estructura química

Deuruxolitinib Estructura química

No. CAS : 1513883-39-0

This product is a controlled substance and not for sale in your territory.

Based on 1 publication(s) in Google Scholar

Other Forms of Deuruxolitinib:

  • Ruxolitinib In-stock
  • (Rac)-Ruxolitinib-d9 Obtener un presupuesto

Ver todos los productos específicos de isoformas JAK:

Ver todas las isoformas
JAK1 JAK2 JAK3 Tyk2 JAK
Descripciòn

Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I)[1].

IC50 & Target[1]

JAK1

 

JAK2

 

In Vitro

"Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[2].
Potential advantages of deuterated compounds:
(1) Extend the half-life in vivo. Deuterated compounds may be able to prolong the pharmacokinetic characteristics of the compound, that is, prolong the half-life in vivo. This can improve compound safety, efficacy and tolerability, and increase ease of administration.
(2) Improve oral bioavailability. Deuterated compounds may reduce the degree of unwanted metabolism (first-pass metabolism) in the gut wall and liver, allowing a greater proportion of the unmetabolized drug to reach its target site of action. High bioavailability determines its activity at low doses and better tolerance.
(3) Improve metabolic characteristics. Deuterated compounds may reduce the formation of toxic or reactive metabolites and improve drug metabolism.
(4) Improve drug safety. Deuterated compounds may reduce or eliminate adverse side effects of pharmaceutical compounds and are safe.
(5) Preserve the therapeutic properties. Deuterated compounds are expected to retain similar biochemical potency and selectivity to hydrogen analogs in previous studies.
"

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Deuruxolitinib Related Antibodies
Ensayo clínico
Peso molecular

314.41

Fòrmula

C17H10D8N6
No. CAS

1513883-39-0
Unlabeled CAS

941678-49-5
Appearance

Solid

Color

White to off-white

SMILES

N#CC[C@@H](N1N=CC(C2=C3C(NC=C3)=NC=N2)=C1)C4C([2H])(C([2H])(C([2H])(C4([2H])[2H])[2H])[2H])[2H]
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvente y solubilidad
In Vitro: 

DMSO : ≥ 125 mg/mL (397.57 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.1806 mL 15.9028 mL 31.8056 mL
5 mM 0.6361 mL 3.1806 mL 6.3611 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Calculadora de molaridad

  • Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Pureza y Documentación

Purity: 99.18%

COA (256 KB) HNMR (265 KB) LCMS (96 KB)

Instrucciones de manejo (2659 KB)
Referencias

  • [1]. Amanda T. WAGNER, et al. Treatment of hair loss disorders with deuterated jak inhibitors. Patent WO2017192905A1

    [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  • [1]. Amanda T. WAGNER, et al. Treatment of hair loss disorders with deuterated jak inhibitors. Patent WO2017192905A1

    [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.1806 mL 15.9028 mL 31.8056 mL 79.5140 mL
5 mM 0.6361 mL 3.1806 mL 6.3611 mL 15.9028 mL
10 mM 0.3181 mL 1.5903 mL 3.1806 mL 7.9514 mL
15 mM 0.2120 mL 1.0602 mL 2.1204 mL 5.3009 mL
20 mM 0.1590 mL 0.7951 mL 1.5903 mL 3.9757 mL
25 mM 0.1272 mL 0.6361 mL 1.2722 mL 3.1806 mL
30 mM 0.1060 mL 0.5301 mL 1.0602 mL 2.6505 mL
40 mM 0.0795 mL 0.3976 mL 0.7951 mL 1.9879 mL
50 mM 0.0636 mL 0.3181 mL 0.6361 mL 1.5903 mL
60 mM 0.0530 mL 0.2650 mL 0.5301 mL 1.3252 mL
80 mM 0.0398 mL 0.1988 mL 0.3976 mL 0.9939 mL
100 mM 0.0318 mL 0.1590 mL 0.3181 mL 0.7951 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Deuruxolitinib Related Classifications

  • Inflammation/Immunology
  • Epigenetics Stem Cell/Wnt Protein Tyrosine Kinase/RTK JAK/STAT Signaling
  • JAK
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Deuruxolitinib1513883-39-0CTP-543Ruxolitinib d8Deuterated RuxolitinibCTP543CTP 543JAKJanus kinasealopecia areataautoimmunedisorderhair lossInhibitorinhibitorinhibit